The Effect of Hormonal Add-Back Therapy in Adolescents Treated With a GnRH Agonist for Endometriosis: A Randomized Trial
Completed
Brigham and Women's Hospital
Phase 2
2007-08-01
The purpose of this study is to determine whether a regimen of norethindrone acetate +
placebo or norethindrone acetate + conjugated estrogens is superior in maintaining skeletal
health and quality of life in adolescents treated with a GnRH agonist for endometriosis.
The Effect of Hormonal Add-Back Therapy in Adolescents Treated With a GnRH Agonist for Endometriosis: A Randomized Trial
Completed
Boston Children's Hospital
Phase 2
2007-08-01
The purpose of this study is to determine whether a regimen of norethindrone acetate +
placebo or norethindrone acetate + conjugated estrogens is superior in maintaining skeletal
health and quality of life in adolescents treated with a GnRH agonist for endometriosis.
The Effect of Hormonal Add-Back Therapy in Adolescents Treated With a GnRH Agonist for Endometriosis: A Randomized Trial
Completed
Boston Children’s Hospital
Phase 2
2007-08-01
The purpose of this study is to determine whether a regimen of norethindrone acetate +
placebo or norethindrone acetate + conjugated estrogens is superior in maintaining skeletal
health and quality of life in adolescents treated with a GnRH agonist for endometriosis.
Pretreatment With Norethindrone Acetate Prior to Levonorgestrel IUS Insertion for Heavy Menstrual Bleeding
Unknown status
Scott and White Hospital & Clinic
Phase 4
2011-01-01
Problematic uterine bleeding after the insertion of the LNG IUS is a well documented side
effect. The levonorgestrel intrauterine system (LNG IUS) was approved for treatment of heavy
menstrual bleeding (HMB) by the FDA in October 2009. To reduce the incidence and severity of
post-insertional uterine bleeding, pretreatment with norethindrone acetate may effectively
slough the endometrium prior to insertion of the LNG IUS.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
